Alto Neuroscience, Inc. (NYSE:ANRO) Stock Holdings Increased by Geode Capital Management LLC

Geode Capital Management LLC grew its position in shares of Alto Neuroscience, Inc. (NYSE:ANRO) by 148.7% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 469,988 shares of the company’s stock after buying an additional 281,018 shares during the period. Geode Capital Management LLC owned about 1.74% of Alto Neuroscience worth $5,378,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in the company. State Street Corp lifted its stake in Alto Neuroscience by 123.7% during the third quarter. State Street Corp now owns 236,857 shares of the company’s stock worth $2,710,000 after purchasing an additional 130,985 shares during the last quarter. Bowie Capital Management LLC bought a new position in shares of Alto Neuroscience in the 2nd quarter worth about $462,000. Jennison Associates LLC boosted its holdings in shares of Alto Neuroscience by 80.3% in the 3rd quarter. Jennison Associates LLC now owns 832,290 shares of the company’s stock valued at $9,521,000 after buying an additional 370,612 shares during the period. TD Asset Management Inc bought a new stake in shares of Alto Neuroscience during the 2nd quarter valued at about $928,000. Finally, BNP Paribas Financial Markets raised its stake in Alto Neuroscience by 619.2% during the third quarter. BNP Paribas Financial Markets now owns 4,315 shares of the company’s stock worth $49,000 after acquiring an additional 3,715 shares during the period.

Analysts Set New Price Targets

Several equities analysts have recently commented on the company. William Blair reaffirmed an “outperform” rating on shares of Alto Neuroscience in a report on Tuesday, September 10th. RODMAN&RENSHAW lowered Alto Neuroscience from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 23rd. Robert W. Baird reduced their price target on shares of Alto Neuroscience from $32.00 to $10.00 and set an “outperform” rating for the company in a report on Wednesday, October 23rd. Wedbush cut shares of Alto Neuroscience from an “outperform” rating to a “neutral” rating and dropped their price objective for the stock from $29.00 to $4.00 in a report on Wednesday, October 23rd. Finally, Stifel Nicolaus reduced their target price on shares of Alto Neuroscience from $32.00 to $10.00 and set a “buy” rating for the company in a research note on Wednesday, November 13th. Three research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, Alto Neuroscience presently has a consensus rating of “Moderate Buy” and a consensus target price of $20.00.

Alto Neuroscience Stock Performance

ANRO stock opened at $4.61 on Friday. The company has a quick ratio of 13.09, a current ratio of 13.10 and a debt-to-equity ratio of 0.05. The company has a 50-day simple moving average of $4.15 and a 200 day simple moving average of $9.20. Alto Neuroscience, Inc. has a fifty-two week low of $3.56 and a fifty-two week high of $24.00.

Alto Neuroscience (NYSE:ANRO) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.62) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.67) by $0.05. As a group, research analysts predict that Alto Neuroscience, Inc. will post -2.54 earnings per share for the current year.

Alto Neuroscience Company Profile

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.